SecBot SecBot

VRAX

Virax Biolabs Group Ltd
Nasdaq· In Vitro & In Vivo Diagnostic Substances· Inc. E9· CIK 0001885827 Biotech & Drug Discovery
$1.22 −0.01 (−1.21%)
Oct 23 4:00 PM ET · prev $1.24
Market cap
$1.7M
Nano cap
Median target
$25.00
+1949% · range $25.00–25.00
1 year
−91.6%
from $14.60 · Oct 27
30 days
−47.3%
from $2.31
52-week range
$1.22–17.20
at the low
Avg volume 20D
206.6K
Oct 5 spike 2.90M
Short interest
🔒 Subscribers only
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 5 reports · 90 days
Balance 2 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/5
Strongest BEARISH Virax Biolabs filed a sticker prospectus supplement to increase the maximum aggregate offering amount under…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • TrendDOWNTREND

    48% below its 50-day average. New closing low $1.22 on Oct 23.

Who's buying

13F
Top holderSharesValue
JANE STREET GROUP, LLC26,385$77.6K
UBS Group AG4$12.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jan 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +1949%.Targets as of Sep 20, 2026.

Recent actions
DateFirmActionRating
Jan 9, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 31, 2025HC Wainwright & Co.
INITIATE
INITIATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jul 14, 2026
Listing
Listing Status: VRAX — Normal (was Deficient)
Virax Biolabs Group Limited - Ordinary Shares | Nasdaq Financial Status Indicator D → N
Jul 9, 2026
Trading halt
Halt Resumed: VRAX — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-09T17:36:12.000Z | Resumed 2026-07-09T17:46:13.000Z
Jul 9, 2026
Trading halt
Trading Halt: VRAX — LUDP (Volatility Trading Pause)
Virax Biolabs Group Limited | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Jul 9, 2026
M&A
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
LONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into…
Jul 9, 2026
Trading halt
Halt Resumed: VRAX — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-09T14:00:45.000Z | Resumed 2026-07-09T14:05:45.000Z

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Jul 9, 2026Volatility PauseResumed
Jul 9, 2026Volatility PauseResumed
Jul 9, 2026Volatility PauseResumed
Jul 9, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 9, 2026 SEC
Virax Biolabs is restructuring its senior management, eliminating the COO role and appointing an Acting Chief…
6-K — Impact 3/10
Sep 4, 2026 SEC
Virax Biolabs filed a sticker prospectus supplement to increase the maximum aggregate offering amount under its…
6-K — Impact 7/10
Sep 4, 2026 SEC
Virax Biolabs Group Ltd filed an EFFECT notice with the SEC on September 3, 2026, indicating that a registration…
EFFECT — Impact 3/10
Jul 14, 2026 Listing status
Listing Status: VRAX — Normal (was Deficient)
Virax Biolabs Group Limited - Ordinary Shares | Nasdaq Financial Status Indicator D → N
Jul 9, 2026 Press
Virax Biolabs is raising $3.3M through exercise of preferred investment options at a reduced price of $6/share, while…
Impact 7/10

SecBot reports

11 filings · 1 press release · 2 bullish · 3 bearish · 6 neutral
All VRAX filing & press-release reports (12)